NEW YORK, June 26, 2017 /PRNewswire/ --
If you want a Stock Review on PFE, MRK, ABBV or JNJ then come over to http://dailystocktracker.com/register/and sign up for your free customized report today. Companies in the Drug Manufacturers space develop and sell medicines and vaccines for a wide range of medical uses. Most of them are structured as corporations, and many offer slightly higher-than-average
New York headquartered Pfizer Inc.'s stock rose 0.32%, finishing last Friday's trading session at $34.17. A total volume of 29.31 million shares was traded, which was above their three months average volume of 21.59 million shares. The Company's shares have gained 6.61% in the last month, 0.50% over the previous three months, and 5.20% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 3.41% and 3.67%, respectively. Additionally, shares of Pfizer, which discovers, develops, manufactures, and sells healthcare products worldwide, have a Relative Strength Index (RSI) of 71.22.
On June 22nd, 2017, Pfizer's board of directors declared a 32-cent Q3 2017 dividend on its common stock, payable September 01st, 2017 to shareholders of record at the close of business on August 04th, 2017. The Q3 2017 cash dividend will be the 315th consecutive quarterly dividend paid by the Company. See our free and comprehensive research report on PFE at:
Shares in New Jersey headquartered Merck & Co. Inc. ended at $66.16, up 0.21% from the last trading session. The stock recorded a trading volume of 13.51 million shares, which was above its three months average volume of 8.95 million shares. The Company's shares have advanced 1.89% in the past month, 4.72% over the previous three months, and 12.38% since the start of this year. The stock is trading 3.84% and 5.37% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Merck, which provides healthcare solutions worldwide, have an RSI of 65.36.
On June 22nd, 2017, Merck, known as MSD outside the US and Canada, and Premier Inc., a leading healthcare improvement company, have expanded their efforts to co-develop and test solutions to help improve patient care and wellness while lowering healthcare spending. One is a preventive care model that seeks to improve adolescent and adult vaccination rates. The other is a chronic disease model that includes a new focus on type-2 diabetes patients at risk of hypoglycemia, as well as osteoporosis identification and treatment. MRK free research report is just a click away at:
On Friday, shares in Illinois-based AbbVie Inc. recorded a trading volume of 7.03 million shares, which was above their three months average volume of 5.63 million shares. The stock declined 0.74%, closing the day at $72.64. The Company's shares have gained 10.18% in the last one month, 10.70% over the previous three months, and 16.00% on an YTD basis. The stock is trading 8.59% above its 50-day moving average and 14.47% above its 200-day moving average. Additionally, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have an RSI of 79.69.
On June 22nd, 2017, research firm Societe Generale upgraded the Company's stock rating from 'Hold' to 'Buy'.
On June 22nd, 2017, AbbVie's board of directors declared a quarterly cash dividend of $0.64 per share, payable on August 15th, 2017, to stockholders of record at the close of business on July 14th, 2017. Sign up for your complimentary report on ABBV at:
Johnson & Johnson
At the close of trading on Friday, shares in New Jersey-based Johnson & Johnson recorded a trading volume of 8.68 million shares, which was higher than their three months average volume of 5.71 million shares. The stock finished the session 0.28% higher at $136.43. The Company's shares have gained 7.00% in the past month, 8.73% in the previous three months, and 18.42% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.30% and 13.47%, respectively. Furthermore, shares of Johnson & Johnson, which together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide, have an RSI of 88.06.
On June 20th, 2017, Johnson & Johnson announced that it will host a conference call for investors on July 18th, 2017, at 8:30 a.m. ET to review Q2 results. Alex Gorsky, Chairman and CEO; Dominic Caruso, Executive Vice President, CFO; and Joseph J. Wolk, Vice President, Investor Relations, will host the call. The webcast may be accessed via the Company's website. Register for free on DailyStockTracker.com and download the latest research report on JNJ at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...View All